RxDoctor Payments Data

Mark Mahoney, DO

Family Medicine · Martinsville, VANPI 1689863615

Payments from drug & device makers

$4,780in general payments, 2019–2025

Across 305 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$753
  • AbbVie$595
  • Lilly USA, LLC$454
  • GSK$350
  • Pfizer$257
  • Abbott$246
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,59196%
  • Education$341%
  • Other$1563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,780 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$316,926
Medicare patients
970
Services billed
6,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$140,860
TrulicityDulaglutide96$106,714
OzempicSemaglutide73$93,108
XareltoRivaroxaban100$75,323
JardianceEmpagliflozin66$57,740
JanuviaSitagliptin Phosphate57$56,199
NuplazidPimavanserin Tartrate11$44,323
VraylarCariprazine Hcl29$43,733
MounjaroTirzepatide36$41,323
Bydureon BciseExenatide Microspheres37$33,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,030
EntrestoSacubitril/Valsartan34$29,757
CreonLipase/Protease/Amylase16$26,490
Tresiba Flextouch U-100Insulin Degludec46$20,114
Tresiba Flextouch U-200Insulin Degludec23$18,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$454$148,038132 claims
PfizerEliquis, Premarin$257$146,290184 claims
Novo NordiskOzempic$753$93,10873 claims
AbbVieVraylar, Creon, Linzess, Namzaric, Restasis$595$90,29893 claims
Johnson & JohnsonXarelto$150$75,323100 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$350$61,185133 claims
Boehringer IngelheimJardiance$84$57,74066 claims
MerckJanuvia$206$56,19957 claims
Acadia Pharmaceuticals IncNuplazid$20$44,32311 claims
NovartisEntresto$108$29,75734 claims
AstraZenecaFarxiga, Lokelma$176$17,89428 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$16,10711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →